



# Comparison of Extrinsic and Intrinsic Dynamic Contrasts in Fast 3D Optical Mammography

C.H. Schmitz<sup>1,2</sup>

Sophie Piper<sup>1</sup>, P.Schneider<sup>1</sup>, N. Volkwein<sup>1</sup>,  
N.Schreiter<sup>1</sup>, A.Poellinger<sup>1</sup>

*<sup>1</sup>Charité University Medicine Berlin*

*<sup>2</sup>NIRx Medizintechnik GmbH, Berlin*


ECBO Munich 2013



# We all know this...


## Promises of optical mammography

- Primary goal: Functional contrasts → higher sensitivity/specificity?  
→ X-Ray Sens.: 75% (50%)
- Secondary goals: Safe technology, etc.



## Challenges of optical mammography:

- Calibration / absolute Hb measurements are difficult
- Image reconstruction unstable
- → Technology not quite as simple/cheap as one thought...



## Where are we:

- Review by Leff et al 2008:  
OM sensitivity approaching 85% in retrospective studies; large prospective database is outstanding

# Our Approach: Dynamic Imaging

- **Interrogate hemodynamics:**

Basic tissue function and physiology (neo-angiogenesis, blunted vascular response, oxygen supply/demand imbalance, extravasation, etc...)

- **Acquire time series of optical tomography images**

(high frame rate & high dynamic range)


- **Stabilize the image reconstruction process:**

Reconstruct relative changes, insensitive to background properties, boundary conditions


Barbour, et al, JOSA A (2001)

# Technology

- **Scanner:**  
DYNOT 232 optical tomography system  
31 sources x 31 detectors = 931 channels  
@ 1.9 Hz



- **Reconstruction:**  
NIRx NAVI Software,  
relative absorption changes in each of  
2243 FEM nodes




C. H. Schmitz et al., *Rev. Sci. Instrum.* (2002)

# Study Design


- 30 women (mean age 53 yrs), scheduled for biopsy at Charité Radiology Clinic
- All received Gd enhanced MRI and biopsy following OM
- 19 malignant / 11 benign
- + 4 healthy controls
- **Intrinsic Contrast:**  
Valsalva Maneuver: Induce a transient increase in blood pressure  
3x Valsalva (15 sec) every 2 min.
- **External Contrast Agent:** Indiocyanine Green (ICG)  
25mg ICG bolus within 5-10 sec *i.v.* (cubital vein)

# Valsalva Maneuver

Raw Data



Reconstructed Data




Features examined:

- FWHM
- PA = Peak amplitude
- TTT = Time-to-Ten Percent




# Valsalva Analysis



- Valsalva highly variable, depends strongly on individual performance
- We retained 10 malignant and 7 benign lesions for analysis
- → Reader-based evaluation of parameter maps

# Parameter Maps



- Two trained readers evaluate maps (FWHM, PA, TTT, both Hb states)
- Best sensitivity ~90% (worst 50-60%)
- Findings not significant (FWHM oxy was best:  $p=0.057$ , sens 70%/spec 85%)

N. Schreiter et al. *Rofo*,184:358-366 (2012).




# Evoked Responses Evaluated

- Strong signal
- Sensitivity to pathophysiological states indicated
- Highly variable if not externally controlled
  
- → breathing gases (carbogen)
- → external control mechanisms
- → external modulation (pressure, ...)
- → bilateral breast imaging (self-referencing)


R. Al abdi et al., JOSA A (2011)

# ICG Bolus Signal

Raw Data




Reconstructed Data




Included: 14/19 malignant, 8/11 benign

# Bolus Peak Mapping



P. Schneider et al. *Rofo*,183(10):956-63 (2011)


# Reader- dependent visual inspection




→ Reader independent tumor detection?

# Peak-Time grouped Amplitude (PTA)

## Mean time courses of voxel with equal peak time




Case 1: 53y, 33mm  
invasive ductal carcinoma



Case 2: 22y  
22mm fibroadenoma



# Mean PTA-curves over all patients



Significant Difference of PTA at TTP= 1.5sec between the malignant and benign lesions (Wilcoxon test,  $p=0.0015$ )



# Reader independent Classification Approach



**Decision Boundary for Reader Independent Classification:  
PTA = 84.4% of the mean bolus signal**

P. Schneider et al. *Rofo*,183(10):956-63 (2011).

# Classification Rates for 22 patients



<b>Malignant, mean lesion size (range)</b>	<b>Detection Rate</b>	<b>Benign, mean lesion size (range)</b>	<b>Detection Rate</b>
<i>Invasive ductal carcinoma , 29mm (8-51mm)</i>	8 / 9	<i>Fibro-cystic mastopathy, 11mm</i>	1 / 1
<i>Invasive lobular carcinoma, 25mm</i>	1 / 1	<i>Fibroadenoma, 24mm (10-51mm)</i>	5 / 6
<i>Invasive lobular ductal carcinoma, 17mm</i>	0 / 1	<i>Pseudoangiomatous stromalhyperplasia (PASH), (44mm)</i>	1 / 1
<i>Metaplastic carcinoma, 28mm (19-37mm)</i>	2 / 2		
<i>Ductal carcinoma in situ, 80mm</i>	1 / 1		
<b>Sens. = 86%</b>		<b>Spec. = 88%</b>	
<b>Sum</b>	<b>12 / 14</b>	<b>Sum</b>	<b>7 / 8</b>

P. Schneider et al. *Rofo*,183(10):956-63 (2011).

## Conclusion

- High-frame rate DOT allows imaging fast tissue dynamics
- Intrinsic and extrinsic tumor contrasts obtainable
- Intrinsic contrast suffers from repeatability  
→ requires control or reference
- Dye bolus kinetics highly replicable,  
fast uptake dynamics allow for sensitive pathological  
assessment

# Acknowledgements

**Dept. of Radiology  
Charité University Medicine Berlin  
Berlin Neuroimaging Center, Charité**

**S. Piper  
P. Schneider,  
N. Volkwein,  
N. Schreiter,  
A. Poellinger**



This research was supported by the National Institutes of Health (NIH) under grants R41CA096102 and R01CA066184, by the U. S. Army under grant DAMD017-03-C-0018, and by the New York State Department of Health. Some of the devices used in this research are a product of NIRx Medical Technologies, LLC.